PECSA
LIVE

Serial Number

97251008

Owner

Bazelet Health Systems, Inc.

Attorney

Steven M Hoffberg

Filing Date

Feb 2, 2022

Add to watchlist:

No watchlists yet
View on USPTO

PECSA Trademark

Serial Number: 97251008

PECSA is a trademark filed by Bazelet Health Systems, Inc. on February 2, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Bazelet Health Systems, Inc. (5 trademarks)

Suite 216
Columbia, MD 21045

Entity Type: 03

Trademark Details

Filing Date

February 2, 2022

Registration Date

Not Registered

Published for Opposition

September 9, 2025

Goods & Services

Medicinal drinks; Medicinal herb extracts, other than essential oils; Medicinal herbal extracts for medical purposes, other than essential oils; Medicinal herbal preparations; Medicinal herbs; Medicinal herbs in dried or preserved form; Medicinal oils, other than essential oils; Medicinal tea; Anti-inflammatory preparations; Beverages containing cannabis extract, cannabigerol, cannabigerolic acid for use as a nutritional supplement; Decoctions of medicinal herb; Dietary supplement beverage for treatment of neurological diseases, seizures, inflammation, viral infection, diabetes, metabolic disorders, free radical excess; Dietary supplements also containing cannabis oil, other than essential oils; full spectrum cannabis herb extract in the nature of concentrated components of cannabis plant for medical purposes, other than essential oils; Dietary supplements consisting primarily of cannabis oil, other than essential oils; Dietary supplements for human beings; Dietary supplements for human consumption; Dietary supplements for treatment of insomnia, sleep disorders, depression, anxiety, neurodegenerative diseases, Alzheimer's disease, dementia, Parkinson's disease, post traumatic stress disorder, phobias, addictions, attention deficit hyperactivity disorder, autism, mood disorders, brain disorders, central nervous system disorders; Dietary supplements in the form of cannabis extract oil, other than essential oils, for medical purposes; Dietary and nutritional supplements containing panakeia extract in the nature of powder, oil and solution for medical purposes, other than essential oils; Dietary beverage supplements for human consumption in liquid and dry mix form for therapeutic purposes; Dietary fiber for treating constipation; Dietary fiber for use as an ingredient in the manufacture of dietary supplements; Dietary food supplements; Dietary supplements; Dietary supplements for humans; Food supplements for treatment of neurological diseases, seizures, inflammation, viral infection, diabetes, metabolic disorders, free radical excess; Health food supplements; Herb tea for medicinal purposes; Herbal extracts for medical purposes, other than essential oils; Herbal supplements; Herbal tea for medicinal purposes; Liquid herbal supplements; Liquid nutritional supplement; Medicinal roots; Natural herbal supplements; Nutraceuticals for use as a dietary supplement; Nutraceuticals for use as a dietary supplement for treatment of insomnia, sleep disorders, depression, anxiety, neurodegenerative diseases, Alzheimer's disease, dementia, Parkinson's disease, post traumatic stress disorder, phobias, addictions, attention deficit hyperactivity disorder, autism, mood disorders, brain disorders, central nervous system disorders; nutritional supplements for the treatment of neurological diseases, seizures, inflammation, viral infection, diabetes, metabolic disorders, free radical excess; Nutritional supplements; Nutritional supplements consisting primarily of cannabis oil, other than essential oils; Nutritional supplements for treatment of neurological diseases, seizures, inflammation, viral infection, diabetes, metabolic disorders, free radical excess; Nutritional supplements for treatment of insomnia, sleep disorders, depression, anxiety, neurodegenerative diseases, Alzheimer's disease, dementia, Parkinson's disease, post traumatic stress disorder, phobias, addictions, attention deficit hyperactivity disorder, autism, mood disorders, brain disorders, central nervous system disorders; Nutritional supplements in the form of oil other than essential oils, ground seeds, capsules, gelcaps; Nutritional food additives for medical purposes in the nature of natural food extracts derived from cannabis; Plant and herb extracts for medicinal purposes, other than essential oils; Plant and herb extracts for medicinal purposes, other than essential oils, sold as components of medicated cosmetics; Plant extracts for medical, veterinary and pharmaceutical purposes, other than essential oils; Plant extracts for pharmaceutical purposes, other than essential oils; all of the foregoing cannabis-related goods containing cannabis ingredients solely derived from hemp with a delta-9-tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis and containing no CBD

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 5, 2026 EXRA
SOU EXTENSION 1 GRANTED
May 5, 2026 EX1G
SOU EXTENSION 1 FILED
May 4, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
May 4, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 4, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 9, 2025 NPUB
PUBLISHED FOR OPPOSITION
Sep 9, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 3, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 8, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 8, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 8, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 8, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 8, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 15, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 14, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 14, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 14, 2023 GNRN
NON-FINAL ACTION E-MAILED
Aug 14, 2023 GNRT
NON-FINAL ACTION WRITTEN
Aug 14, 2023 CNRT
ASSIGNED TO EXAMINER
Jul 17, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 8, 2022 NWOS
NEW APPLICATION ENTERED
Feb 5, 2022 NWAP